RAY1225 (Bilpatide)_Dosage, benefits & legal status
Also known as bilpatide, RAY-1225
A fortnightly dual agonist with a topline nobody can place in time.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is RAY1225 (Bilpatide)?
Plain language first. The technical label stays, but it never stands alone.Overview
This is a Chinese weight-loss injection that hits the same two receptors as tirzepatide, with one practical difference worth noting: it is given every two weeks instead of every week. Its mid-stage trial results are good and properly published as a conference abstract, with weight loss rising steadily across six doses up to about 21% at the top dose. The problem is the phase 3 announcement everyone is quoting. The company said the trial succeeded and gave a 22.24% figure, but did not say at what week, in how many people, or with what side effects. Work backward from the two numbers it did give and the comparison group appears to have lost less weight than the comparison groups in its own earlier trial. That usually means the two sets of numbers are not measuring the same thing.
RAY1225 is a synthetic GLP-1 and GIP dual receptor agonist developed by Raynovent, part of Zhongsheng Pharmaceutical, and dosed subcutaneously once every two weeks rather than weekly. Bilpatide is its proposed International Nonproprietary Name, appearing in WHO Proposed INN List 135 of July 2026 with the stated action of GIP and GLP-1 receptor agonist, antidiabetic. The published chemical name indicates a bridge spanning two lysine residues and a C-terminus ending in a tripeptide of proline residues followed by a serinamide, features that together point to a constrained or stapled peptide rather than a fusion protein, though the full sequence, formula, molecular weight and CAS number are not in any record we could reach. No discovery or pharmacology paper for the compound exists.
What it's used for
Investigational for obesity and weight management, with separate testing in type 2 diabetes. It is not approved anywhere and is not sold.
How does RAY1225 (Bilpatide) work?
What it does in the body, and where.The receptor targets are the same pair tirzepatide hits. Two things set this compound apart, one practical and one a claim nobody has shown the data for.
- 01Two receptors, one moleculeGLP-1 and GIP are both gut hormones released after eating. Activating the GLP-1 receptor slows stomach emptying, suppresses appetite and releases insulin in proportion to glucose. Adding GIP receptor activity appears to improve weight loss beyond what GLP-1 alone achieves, and that is the basis of the whole dual agonist class. Nothing about this compound's receptor pharmacology is novel.
- 02Built to last a fortnightMost of this class is weekly. The published chemical name points to a bridge spanning two lysine residues, a constraint that rigidifies the peptide and typically slows enzymatic breakdown, with a C-terminus of three prolines and a serinamide. A molecule engineered to survive two weeks rather than one is a real differentiator for anyone who dislikes injections, and the entire clinical program uses the two-week interval.
- 03The biased claim appears in one place onlyThe title of the phase 2 conference abstract describes this as a biased GLP-1 and GIP receptor agonist. Biased agonism means preferentially triggering some signaling pathways downstream of a receptor while sparing others, and it is a specific pharmacological claim with real consequences for efficacy and side effects. That word appears nowhere in the company's own filings, where it is called a plain dual agonist, and no readable receptor signaling data supports it. By contrast the paper describing its closest Chinese rival calls that molecule balanced. Two opposite characterizations, neither backed by data a reader can check.
- 04What is missing from the recordThere is no sequence, no molecular weight, no formula, no CAS number and no FDA substance registry entry for this compound, and no discovery or pharmacology paper exists. The entire public evidence base is three conference abstracts and a set of company announcements. For a compound with a completed phase 3, that is a thin foundation, and it is the reason this page leans on what can be checked rather than on what has been claimed.
A schematic of the compound's mechanism, not a diagnostic image.
What else is it used for?
Each group carries its own evidence level.Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
The published phase 2 is solid
peer-reviewed-human- Human trial231 participants, six doses every two weeks, week 24 primary: weight loss 9.73% to 21.18% against 2.96% on placebo, all p below 0.001.
- Human trialA clean dose-response with no plateau through 18 mg, unusual in this class.
- No dataNo drug-related serious adverse events reported, but no adverse event percentages and no discontinuation rate given.
- Human trialDiabetes program: HbA1c down 1.67%, 2.07% and 2.24% against 0.23% on placebo, p below 0.0001.
The phase 3 topline will not reconcile
none- No dataAnnounced October 8, 2026 as 22.24% and 20.46% for the 9 mg group, with no timepoint, no enrollment and no safety data.
- No dataThe two figures imply a placebo arm losing about 1.78%, below the 2.96% and 3.62% placebo arms in the same program's phase 2.
- No dataPhase 2 at the same 9 mg dose gave 14.75% at week 24, so the phase 3 number implies a later timepoint or a different population.
- No dataNo registry record carries the phase 3 trial's name, so even identifying which record it is remains inference.
Naming and identity
none- RegulatoryBilpatide is a proposed INN from WHO Proposed List 135, July 2026, absent from the three preceding lists. Proposed, not recommended.
- No dataNo sequence, molecular weight, formula, CAS number or FDA substance registry entry exists, and there is no discovery or pharmacology paper.
- No dataSearching for a bilpatide identifier in the FDA substance registry returns a record belonging to bivalirudin, an unrelated anticoagulant.
- No dataThe biased agonist claim appears only in the conference abstract title, never in company filings, with no readable supporting data.
Registry records contradict the company
none- No dataThe phase 2 record still reads Recruiting, verified February 2025, while the Chinese registry records completion in November 2025.
- No dataPrimary outcome timeframe says week 26 where both abstracts report week 24. Enrollment is given as 270, 243 and 231 across sources.
- RegulatoryThe US step was FDA clearance to run a phase 2 trial, not an approval. No new drug application found anywhere.
The headline error is the phase 3 weight-loss figure. The 22.24% announced in October 2026 came with no timepoint, no enrollment and no safety data, so it cannot be compared with published results for tirzepatide or retatrutide, since those always carry a week. Two internal checks show why caution is needed: the pair of figures released implies a placebo arm that lost about 1.78%, less than the placebo arms in the company's own phase 2, and the phase 2 at the same 9 mg dose produced 14.75% at week 24. The second error is the partnership value. The widely reported one billion yuan is a ceiling including all milestones; the signed January 2026 agreement provides 200 million yuan upfront plus up to 800 million in milestones and royalties, for Greater China rights only. The third is calling the US regulatory step an approval, when the FDA cleared a phase 2 trial. The fourth is the biased agonist description, found only in a conference abstract title and in no company filing, while the paper on its closest rival calls that molecule balanced instead. Last, anyone looking up an identifier for bilpatide should know that the obvious search returns a record for bivalirudin, a completely unrelated drug.
The published record
Papers about RAY1225 (Bilpatide)
Searched: RAY1225, bilpatide, bilpatidum.
Left out: bivalirudin (observed trap: searching for a bilpatide identifier in the FDA substance registry returns the bivalirudin record, CAS 128270-60-0, an unrelated anticoagulant. Anyone chasing an identifier for this compound will land there); tirzepatide (the class benchmark and the comparator readers want, with an enormous literature that is not about this molecule); GIP (the receptor class term, shared with tirzepatide, retatrutide, maritide and others that have their own slugs); GLP-1 (the receptor class term, tens of thousands of records); REBUILDING (the sponsor's trial program name. It appears in NO registry record at all, so it retrieves unrelated uses of an ordinary English word); SHINING (the sponsor's other program name, also absent from every registry record); Qilu (the commercialization partner, a company name spanning a portfolio).
12 papers tagged human · 0 not reviews or lab · 0 clinical trial publications
12 registered trials · none with posted results
Furthest stage reached: Phase 3, under way
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count. A preprint and its journal version count once.
At a glance
Four things to know about RAY1225 (Bilpatide)
Evidence
Investigational
Category
Weight loss and metabolic
Common vial
Varies
Half-life
Long enough for dosing every 2 weeks; no published figure located
How much, and do you cycle it?
The range, and whether you take breaks.3 to 18 mg every 2 weeks across the phase 2 dose range, every 2 weeks. Continuous dosing every 2 weeks Trial dose
Trialed as a chronic treatment on a fortnightly schedule, titrated upward rather than cycled.
Long enough for dosing every 2 weeks; no published figure locatedNo figure
The entire clinical program doses every two weeks, so the half-life must be of the order of a week or more, but no measured value appears in any reachable source. No pharmacokinetic paper for this compound exists.
You can compare this against the whole library to see where it sits.
How is it given?
Dosing context and source notes.Investigational and not sold, so no vial draw can be shown and the calculator does not apply. The phase 2 tested six dose levels from 3 to 18 mg every two weeks. No dose amounts appear in any of the obesity registry records, and the only registry entry carrying real doses lists 3, 6 and 9 mg every two weeks.
How do you store it?
Before mixing, and after.Nothing to store: it is not sold anywhere.
RAY1225 (Bilpatide) has never been marketed, so there is no vial, pen or bottle to keep at home. Supplies for a trial are made, stored and dispensed by the sponsor and the trial pharmacy under conditions set in the protocol. Anything offered for sale under this name did not come from that supply chain.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- Comparing the 22.24% phase 3 figure with published results for other drugs, since no timepoint was stated for it and the comparable phase 2 figure at the same dose was 14.75% at week 24
- Treating the US regulatory step as an approval: what was granted was clearance to run a phase 2 trial
- Reading the reported partnership value as money received, since the headline figure is a ceiling including milestones
Stop and get help
- Severe or persistent abdominal pain, a possible sign of pancreatitis in this drug class
- Persistent vomiting with an inability to keep fluids down
- Signs of an allergic reaction, including rash, swelling or difficulty breathing
Common effects
- Gastrointestinal effects, as with every GLP-1 and GIP dual agonist. No percentages have been published.
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is RAY1225 (Bilpatide) approved?
And where the numbers on this page come from.No. RAY1225 (Bilpatide) is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteUnder the skin (subcutaneous injection, every 2 weeks)
- Checked2 November 2026
- DoseFrom published clinical trials. Not approved by a regulator for this dose.
- Vial sizeFrom what vendors typically list; not a recommendation.
- Sources
What has happened recently
Nothing is approved. In China the compound holds trial authorizations, and in the United States the FDA cleared a phase 2 trial following a December 2024 submission. That is permission to run a study rather than any form of marketing approval, and no new drug application has been found in any jurisdiction. The commercial arrangement is frequently reported as a one billion yuan deal with Qilu Pharmaceutical. The agreement, signed January 16, 2026, licenses manufacture and commercialization in Greater China to Qilu for 200 million yuan upfront plus up to 800 million yuan in milestones and double-digit royalties, with Raynovent keeping global intellectual property and rights outside China. One billion is therefore the ceiling if every milestone is met, not cash received. The naming position is worth stating precisely because it differs from its closest rival: bilpatide is a proposed International Nonproprietary Name, published in WHO Proposed INN List 135 in July 2026 and absent from the three preceding lists, so it is proposed rather than recommended. The WHO entry names no sponsor, and the link between bilpatide and RAY1225 comes from the company's own announcements. A warning for anyone looking the compound up: searching for a bilpatide identifier in the FDA substance registry returns a record that actually belongs to bivalirudin, an unrelated anticoagulant.
You can compare this against the whole library, or read how to check a seller.
What else is like RAY1225 (Bilpatide)?
Others in GLP-1 agonists, side by side.If you're weighing RAY1225 (Bilpatide), it's worth reading Ribupatide, VK2735, and Zabopegdutide (DD01) in the same class.
A fortnightly dual agonist with a topline nobody can place in time.
- Dose
- 3 to 18 mg every 2 weeks across the phase 2 dose range
- How often
- Every 2 weeks
An experimental weekly GLP-1/GIP shot from China, now in a 4,900-person phase 3 program.
- Dose
- 2 up to 10 mg per week (trial doses)
- How often
- Weekly
An experimental weight-loss compound in the tirzepatide family, as a shot or pill.
- Dose
- 2.5 up to 15 mg per week (start low, increase slowly)
- How often
- Weekly
Nearly the same peptide as efinopegdutide, carried on a large PEG instead of an antibody fragment. In a 67-person phase 2, 76% on the drug cut liver fat by at least 30% in 12 weeks, against 12% on placebo.
- Dose
- 20 mg weekly for 2 weeks, then 40 mg weekly (phase 2 trial)
- How often
- Weekly
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- Diabetes, abstract 1227-OR, RAY1225 phase 2 for weight management(2026)Volume 75, presented June 7, 2026. The phase 2 in 231 participants across six dose levels given every two weeks, with a week 24 primary endpoint. Least-squares mean weight change was 9.73% at 3 mg, 12.68% at 6 mg, 14.75% at 9 mg, 14.13% at 12 mg, 14.92% at 15 mg and 21.18% at 18 mg, against 2.96% on placebo, all p below 0.001. No drug-related serious adverse events were reported, but the abstract gives no adverse event percentages and no discontinuation rate. The title describes the compound as a biweekly biased GLP-1 and GIP receptor agonist, the only place the biased claim appears.
- Diabetes, abstract 795-P, RAY1225 every two weeks in type 2 diabetes(2025)Volume 74, presented June 20, 2025. The diabetes program, reporting HbA1c reductions of 1.67%, 2.07% and 2.24% against 0.23% on placebo, p below 0.0001. Useful as the other half of the clinical picture, since the obesity program gets all the attention.
- ClinicalTrials.gov record NCT06254261, the phase 2 obesity trial(2026)The registry record for the published phase 2, and a good illustration of why Chinese trial records need cross-checking. It still reads Recruiting, last verified February 2025, while the corresponding Chinese registry entry records the trial as completed in November 2025 and the final data were presented in June 2026. Its primary outcome timeframe says week 26 where both conference abstracts report week 24. Enrollment disagrees three ways across sources: 270 estimated, 243 actual in the Chinese registry, and 231 in the abstract.
- WHO Drug Information, Proposed International Nonproprietary Names List 135(2026)Bilpatide, Latin bilpatidum, appears in Proposed INN List 135, published July 20, 2026, with the stated action GIP and GLP-1 receptor agonist, antidiabetic. It is absent from the three preceding proposed lists, each checked separately, so the name is newly proposed rather than recommended. The WHO entry names no sponsor; the identification with RAY1225 comes from the developer's own announcements. This matters by contrast with its closest rival, poterepatide, absent from every WHO list.
Beyond these, 13 records are indexed. Browse the records